DexCom, Inc.
Get $10 bonus on your first $100 deposit for DXCM
Get $10 bonus on your first $100 deposit for DXCM
DexCom, Inc. (DXCM) Stock Competitors & Peer Comparison
See (DXCM) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| DXCM | $62.22 | -0.24% | 24.3B | 29.77 | $2.09 | N/A |
| ABT | $102.87 | +0.48% | 178.8B | 27.65 | $3.72 | +2.33% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| SYK | $331.54 | +0.65% | 126.9B | 39.47 | $8.40 | +1.04% |
| MDT | $86.63 | +0.66% | 111.2B | 24.20 | $3.58 | +3.28% |
| BSX | $62.82 | +1.32% | 93.2B | 32.38 | $1.94 | N/A |
| EW | $81.05 | -0.26% | 47.1B | 44.78 | $1.81 | N/A |
| BRKRP | $290.04 | +0.88% | 44B | N/A | N/A | +0.54% |
| PHG | $27.11 | -0.66% | 26B | 25.10 | $1.08 | +3.27% |
| STE | $218.71 | -0.56% | 21.5B | 30.50 | $7.17 | +1.12% |
Stock Comparison
DXCM vs ABT Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, ABT has a market cap of 178.8B. Regarding current trading prices, DXCM is priced at $62.22, while ABT trades at $102.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas ABT's P/E ratio is 27.65. In terms of profitability, DXCM's ROE is +0.32%, compared to ABT's ROE of +0.13%. Regarding short-term risk, DXCM is more volatile compared to ABT. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check ABT's competition here
DXCM vs BSX-PA Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, DXCM is priced at $62.22, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, DXCM's ROE is +0.32%, compared to BSX-PA's ROE of +0.13%. Regarding short-term risk, DXCM is more volatile compared to BSX-PA. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check BSX-PA's competition here
DXCM vs SYK Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, SYK has a market cap of 126.9B. Regarding current trading prices, DXCM is priced at $62.22, while SYK trades at $331.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas SYK's P/E ratio is 39.47. In terms of profitability, DXCM's ROE is +0.32%, compared to SYK's ROE of +0.15%. Regarding short-term risk, DXCM is more volatile compared to SYK. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check SYK's competition here
DXCM vs MDT Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, MDT has a market cap of 111.2B. Regarding current trading prices, DXCM is priced at $62.22, while MDT trades at $86.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas MDT's P/E ratio is 24.20. In terms of profitability, DXCM's ROE is +0.32%, compared to MDT's ROE of +0.10%. Regarding short-term risk, DXCM is more volatile compared to MDT. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check MDT's competition here
DXCM vs BSX Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, BSX has a market cap of 93.2B. Regarding current trading prices, DXCM is priced at $62.22, while BSX trades at $62.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas BSX's P/E ratio is 32.38. In terms of profitability, DXCM's ROE is +0.32%, compared to BSX's ROE of +0.13%. Regarding short-term risk, DXCM is more volatile compared to BSX. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check BSX's competition here
DXCM vs EW Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, EW has a market cap of 47.1B. Regarding current trading prices, DXCM is priced at $62.22, while EW trades at $81.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas EW's P/E ratio is 44.78. In terms of profitability, DXCM's ROE is +0.32%, compared to EW's ROE of +0.10%. Regarding short-term risk, DXCM is more volatile compared to EW. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check EW's competition here
DXCM vs BRKRP Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, BRKRP has a market cap of 44B. Regarding current trading prices, DXCM is priced at $62.22, while BRKRP trades at $290.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas BRKRP's P/E ratio is N/A. In terms of profitability, DXCM's ROE is +0.32%, compared to BRKRP's ROE of -0.00%. Regarding short-term risk, DXCM is less volatile compared to BRKRP. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check BRKRP's competition here
DXCM vs PHG Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, PHG has a market cap of 26B. Regarding current trading prices, DXCM is priced at $62.22, while PHG trades at $27.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas PHG's P/E ratio is 25.10. In terms of profitability, DXCM's ROE is +0.32%, compared to PHG's ROE of +0.08%. Regarding short-term risk, DXCM is more volatile compared to PHG. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check PHG's competition here
DXCM vs STE Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, STE has a market cap of 21.5B. Regarding current trading prices, DXCM is priced at $62.22, while STE trades at $218.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas STE's P/E ratio is 30.50. In terms of profitability, DXCM's ROE is +0.32%, compared to STE's ROE of +0.10%. Regarding short-term risk, DXCM is more volatile compared to STE. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check STE's competition here
DXCM vs ZBH Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, ZBH has a market cap of 18B. Regarding current trading prices, DXCM is priced at $62.22, while ZBH trades at $90.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas ZBH's P/E ratio is 25.60. In terms of profitability, DXCM's ROE is +0.32%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, DXCM is more volatile compared to ZBH. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check ZBH's competition here
DXCM vs ABMD Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, DXCM is priced at $62.22, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas ABMD's P/E ratio is 65.36. In terms of profitability, DXCM's ROE is +0.32%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, DXCM is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check ABMD's competition here
DXCM vs PODD Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, PODD has a market cap of 14.4B. Regarding current trading prices, DXCM is priced at $62.22, while PODD trades at $204.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas PODD's P/E ratio is 58.71. In terms of profitability, DXCM's ROE is +0.32%, compared to PODD's ROE of +0.17%. Regarding short-term risk, DXCM is more volatile compared to PODD. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check PODD's competition here
DXCM vs SNN Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, SNN has a market cap of 13.7B. Regarding current trading prices, DXCM is priced at $62.22, while SNN trades at $32.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas SNN's P/E ratio is 22.47. In terms of profitability, DXCM's ROE is +0.32%, compared to SNN's ROE of +0.12%. Regarding short-term risk, DXCM is more volatile compared to SNN. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check SNN's competition here
DXCM vs PEN Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, PEN has a market cap of 13B. Regarding current trading prices, DXCM is priced at $62.22, while PEN trades at $330.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas PEN's P/E ratio is 73.25. In terms of profitability, DXCM's ROE is +0.32%, compared to PEN's ROE of +0.13%. Regarding short-term risk, DXCM is more volatile compared to PEN. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check PEN's competition here
DXCM vs SWAV Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, DXCM is priced at $62.22, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas SWAV's P/E ratio is 78.76. In terms of profitability, DXCM's ROE is +0.32%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, DXCM is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check SWAV's competition here
DXCM vs ALGN Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, ALGN has a market cap of 12.2B. Regarding current trading prices, DXCM is priced at $62.22, while ALGN trades at $170.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas ALGN's P/E ratio is 30.14. In terms of profitability, DXCM's ROE is +0.32%, compared to ALGN's ROE of +0.10%. Regarding short-term risk, DXCM is less volatile compared to ALGN. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check ALGN's competition here
DXCM vs GMED Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, GMED has a market cap of 11.9B. Regarding current trading prices, DXCM is priced at $62.22, while GMED trades at $87.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas GMED's P/E ratio is 22.43. In terms of profitability, DXCM's ROE is +0.32%, compared to GMED's ROE of +0.12%. Regarding short-term risk, DXCM is less volatile compared to GMED. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check GMED's competition here
DXCM vs BIO-B Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, BIO-B has a market cap of 7.6B. Regarding current trading prices, DXCM is priced at $62.22, while BIO-B trades at $280.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas BIO-B's P/E ratio is 10.06. In terms of profitability, DXCM's ROE is +0.32%, compared to BIO-B's ROE of +0.11%. Regarding short-term risk, DXCM is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check BIO-B's competition here
DXCM vs BIO Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, BIO has a market cap of 7.6B. Regarding current trading prices, DXCM is priced at $62.22, while BIO trades at $279.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas BIO's P/E ratio is 10.05. In terms of profitability, DXCM's ROE is +0.32%, compared to BIO's ROE of +0.11%. Regarding short-term risk, DXCM and BIO have similar daily volatility (3.71).Check BIO's competition here
DXCM vs GKOS Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, GKOS has a market cap of 6.5B. Regarding current trading prices, DXCM is priced at $62.22, while GKOS trades at $112.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas GKOS's P/E ratio is -34.38. In terms of profitability, DXCM's ROE is +0.32%, compared to GKOS's ROE of -0.25%. Regarding short-term risk, DXCM is less volatile compared to GKOS. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check GKOS's competition here
DXCM vs BRKR Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, BRKR has a market cap of 5.6B. Regarding current trading prices, DXCM is priced at $62.22, while BRKR trades at $36.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas BRKR's P/E ratio is -245.07. In terms of profitability, DXCM's ROE is +0.32%, compared to BRKR's ROE of -0.00%. Regarding short-term risk, DXCM is less volatile compared to BRKR. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check BRKR's competition here
DXCM vs NARI Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, DXCM is priced at $62.22, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas NARI's P/E ratio is -59.24. In terms of profitability, DXCM's ROE is +0.32%, compared to NARI's ROE of -0.00%. Regarding short-term risk, DXCM is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check NARI's competition here
DXCM vs IRTC Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, IRTC has a market cap of 3.8B. Regarding current trading prices, DXCM is priced at $62.22, while IRTC trades at $116.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas IRTC's P/E ratio is -84.03. In terms of profitability, DXCM's ROE is +0.32%, compared to IRTC's ROE of -0.38%. Regarding short-term risk, DXCM is less volatile compared to IRTC. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check IRTC's competition here
DXCM vs AXNX Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, DXCM is priced at $62.22, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas AXNX's P/E ratio is -709.80. In terms of profitability, DXCM's ROE is +0.32%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, DXCM is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check AXNX's competition here
DXCM vs LIVN Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, LIVN has a market cap of 3.5B. Regarding current trading prices, DXCM is priced at $62.22, while LIVN trades at $63.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas LIVN's P/E ratio is -14.33. In terms of profitability, DXCM's ROE is +0.32%, compared to LIVN's ROE of -0.21%. Regarding short-term risk, DXCM is less volatile compared to LIVN. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check LIVN's competition here
DXCM vs TMDX Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, TMDX has a market cap of 3.5B. Regarding current trading prices, DXCM is priced at $62.22, while TMDX trades at $100.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas TMDX's P/E ratio is 20.68. In terms of profitability, DXCM's ROE is +0.32%, compared to TMDX's ROE of +0.54%. Regarding short-term risk, DXCM is less volatile compared to TMDX. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check TMDX's competition here
DXCM vs ITGR Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, ITGR has a market cap of 3B. Regarding current trading prices, DXCM is priced at $62.22, while ITGR trades at $86.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas ITGR's P/E ratio is 30.05. In terms of profitability, DXCM's ROE is +0.32%, compared to ITGR's ROE of +0.06%. Regarding short-term risk, DXCM is more volatile compared to ITGR. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check ITGR's competition here
DXCM vs NUVA Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, DXCM is priced at $62.22, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas NUVA's P/E ratio is 75.00. In terms of profitability, DXCM's ROE is +0.32%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, DXCM is more volatile compared to NUVA. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check NUVA's competition here
DXCM vs AXGN Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, AXGN has a market cap of 1.8B. Regarding current trading prices, DXCM is priced at $62.22, while AXGN trades at $34.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas AXGN's P/E ratio is -101.29. In terms of profitability, DXCM's ROE is +0.32%, compared to AXGN's ROE of -0.13%. Regarding short-term risk, DXCM is less volatile compared to AXGN. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check AXGN's competition here
DXCM vs ESTA Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, ESTA has a market cap of 1.7B. Regarding current trading prices, DXCM is priced at $62.22, while ESTA trades at $58.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas ESTA's P/E ratio is -33.90. In terms of profitability, DXCM's ROE is +0.32%, compared to ESTA's ROE of -2.02%. Regarding short-term risk, DXCM is more volatile compared to ESTA. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check ESTA's competition here
DXCM vs ATEC Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, ATEC has a market cap of 1.6B. Regarding current trading prices, DXCM is priced at $62.22, while ATEC trades at $10.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas ATEC's P/E ratio is -11.28. In terms of profitability, DXCM's ROE is +0.32%, compared to ATEC's ROE of -17.60%. Regarding short-term risk, DXCM is less volatile compared to ATEC. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check ATEC's competition here
DXCM vs AORT Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, AORT has a market cap of 1.6B. Regarding current trading prices, DXCM is priced at $62.22, while AORT trades at $34.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas AORT's P/E ratio is 162.90. In terms of profitability, DXCM's ROE is +0.32%, compared to AORT's ROE of +0.02%. Regarding short-term risk, DXCM is less volatile compared to AORT. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check AORT's competition here
DXCM vs AHCO Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, AHCO has a market cap of 1.6B. Regarding current trading prices, DXCM is priced at $62.22, while AHCO trades at $12.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas AHCO's P/E ratio is -23.13. In terms of profitability, DXCM's ROE is +0.32%, compared to AHCO's ROE of -0.05%. Regarding short-term risk, DXCM is more volatile compared to AHCO. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check AHCO's competition here
DXCM vs INSP Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, INSP has a market cap of 1.6B. Regarding current trading prices, DXCM is priced at $62.22, while INSP trades at $54.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas INSP's P/E ratio is 11.25. In terms of profitability, DXCM's ROE is +0.32%, compared to INSP's ROE of +0.21%. Regarding short-term risk, DXCM is less volatile compared to INSP. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check INSP's competition here
DXCM vs PMI Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, PMI has a market cap of 1.5B. Regarding current trading prices, DXCM is priced at $62.22, while PMI trades at $0.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas PMI's P/E ratio is -1.27. In terms of profitability, DXCM's ROE is +0.32%, compared to PMI's ROE of +2.17%. Regarding short-term risk, DXCM is less volatile compared to PMI. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check PMI's competition here
DXCM vs UFPT Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, UFPT has a market cap of 1.5B. Regarding current trading prices, DXCM is priced at $62.22, while UFPT trades at $192.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas UFPT's P/E ratio is 21.95. In terms of profitability, DXCM's ROE is +0.32%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, DXCM is less volatile compared to UFPT. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check UFPT's competition here
DXCM vs PRCT Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, PRCT has a market cap of 1.4B. Regarding current trading prices, DXCM is priced at $62.22, while PRCT trades at $25.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas PRCT's P/E ratio is -14.60. In terms of profitability, DXCM's ROE is +0.32%, compared to PRCT's ROE of -0.25%. Regarding short-term risk, DXCM is less volatile compared to PRCT. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check PRCT's competition here
DXCM vs HSKA Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, DXCM is priced at $62.22, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas HSKA's P/E ratio is -62.49. In terms of profitability, DXCM's ROE is +0.32%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, DXCM is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check HSKA's competition here
DXCM vs TNDM Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, TNDM has a market cap of 1.3B. Regarding current trading prices, DXCM is priced at $62.22, while TNDM trades at $18.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas TNDM's P/E ratio is -6.12. In terms of profitability, DXCM's ROE is +0.32%, compared to TNDM's ROE of -1.42%. Regarding short-term risk, DXCM is less volatile compared to TNDM. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check TNDM's competition here
DXCM vs IRMD Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, IRMD has a market cap of 1.2B. Regarding current trading prices, DXCM is priced at $62.22, while IRMD trades at $96.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas IRMD's P/E ratio is 54.99. In terms of profitability, DXCM's ROE is +0.32%, compared to IRMD's ROE of +0.24%. Regarding short-term risk, DXCM is more volatile compared to IRMD. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check IRMD's competition here
DXCM vs SILK Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, DXCM is priced at $62.22, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas SILK's P/E ratio is -18.96. In terms of profitability, DXCM's ROE is +0.32%, compared to SILK's ROE of -0.35%. Regarding short-term risk, DXCM is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check SILK's competition here
DXCM vs FNA Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, DXCM is priced at $62.22, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas FNA's P/E ratio is -19.83. In terms of profitability, DXCM's ROE is +0.32%, compared to FNA's ROE of -0.17%. Regarding short-term risk, DXCM is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check FNA's competition here
DXCM vs CNMD Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, CNMD has a market cap of 1.1B. Regarding current trading prices, DXCM is priced at $62.22, while CNMD trades at $34.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas CNMD's P/E ratio is 23.04. In terms of profitability, DXCM's ROE is +0.32%, compared to CNMD's ROE of +0.05%. Regarding short-term risk, DXCM is less volatile compared to CNMD. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check CNMD's competition here
DXCM vs BFLY Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, BFLY has a market cap of 1B. Regarding current trading prices, DXCM is priced at $62.22, while BFLY trades at $4.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas BFLY's P/E ratio is -13.26. In terms of profitability, DXCM's ROE is +0.32%, compared to BFLY's ROE of -0.35%. Regarding short-term risk, DXCM is less volatile compared to BFLY. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check BFLY's competition here
DXCM vs SSII Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, SSII has a market cap of 971.8M. Regarding current trading prices, DXCM is priced at $62.22, while SSII trades at $5.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas SSII's P/E ratio is -83.33. In terms of profitability, DXCM's ROE is +0.32%, compared to SSII's ROE of -0.30%. Regarding short-term risk, DXCM is less volatile compared to SSII. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check SSII's competition here
DXCM vs LMRI Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, LMRI has a market cap of 884.2M. Regarding current trading prices, DXCM is priced at $62.22, while LMRI trades at $9.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas LMRI's P/E ratio is -14.17. In terms of profitability, DXCM's ROE is +0.32%, compared to LMRI's ROE of -0.18%. Regarding short-term risk, DXCM is less volatile compared to LMRI. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check LMRI's competition here
DXCM vs INMD Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, INMD has a market cap of 873.7M. Regarding current trading prices, DXCM is priced at $62.22, while INMD trades at $13.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas INMD's P/E ratio is 9.64. In terms of profitability, DXCM's ROE is +0.32%, compared to INMD's ROE of +0.15%. Regarding short-term risk, DXCM is more volatile compared to INMD. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check INMD's competition here
DXCM vs CSII Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, CSII has a market cap of 844M. Regarding current trading prices, DXCM is priced at $62.22, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas CSII's P/E ratio is -20.83. In terms of profitability, DXCM's ROE is +0.32%, compared to CSII's ROE of -0.14%. Regarding short-term risk, DXCM is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check CSII's competition here
DXCM vs IART Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, IART has a market cap of 742.7M. Regarding current trading prices, DXCM is priced at $62.22, while IART trades at $9.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas IART's P/E ratio is -1.41. In terms of profitability, DXCM's ROE is +0.32%, compared to IART's ROE of -0.44%. Regarding short-term risk, DXCM is less volatile compared to IART. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check IART's competition here
DXCM vs CRY Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, DXCM is priced at $62.22, while CRY trades at $17.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas CRY's P/E ratio is 425.71. In terms of profitability, DXCM's ROE is +0.32%, compared to CRY's ROE of +0.02%. Regarding short-term risk, DXCM is less volatile compared to CRY. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check CRY's competition here
DXCM vs CBLL Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, CBLL has a market cap of 699M. Regarding current trading prices, DXCM is priced at $62.22, while CBLL trades at $18.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas CBLL's P/E ratio is -12.63. In terms of profitability, DXCM's ROE is +0.32%, compared to CBLL's ROE of -0.32%. Regarding short-term risk, DXCM is more volatile compared to CBLL. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check CBLL's competition here
DXCM vs AVNS Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, AVNS has a market cap of 648.7M. Regarding current trading prices, DXCM is priced at $62.22, while AVNS trades at $13.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas AVNS's P/E ratio is -8.89. In terms of profitability, DXCM's ROE is +0.32%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, DXCM is more volatile compared to AVNS. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check AVNS's competition here
DXCM vs SRDX Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, DXCM is priced at $62.22, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas SRDX's P/E ratio is -34.66. In terms of profitability, DXCM's ROE is +0.32%, compared to SRDX's ROE of -0.16%. Regarding short-term risk, DXCM is more volatile compared to SRDX. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check SRDX's competition here
DXCM vs BVS Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, BVS has a market cap of 604.3M. Regarding current trading prices, DXCM is priced at $62.22, while BVS trades at $8.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas BVS's P/E ratio is 27.18. In terms of profitability, DXCM's ROE is +0.32%, compared to BVS's ROE of +0.14%. Regarding short-term risk, DXCM is more volatile compared to BVS. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check BVS's competition here
DXCM vs CTKB Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, CTKB has a market cap of 582.3M. Regarding current trading prices, DXCM is priced at $62.22, while CTKB trades at $4.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas CTKB's P/E ratio is -8.71. In terms of profitability, DXCM's ROE is +0.32%, compared to CTKB's ROE of -0.18%. Regarding short-term risk, DXCM is less volatile compared to CTKB. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check CTKB's competition here
DXCM vs APEN Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, DXCM is priced at $62.22, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas APEN's P/E ratio is -9.43. In terms of profitability, DXCM's ROE is +0.32%, compared to APEN's ROE of -0.85%. Regarding short-term risk, DXCM is more volatile compared to APEN. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check APEN's competition here
DXCM vs SIBN Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, SIBN has a market cap of 579.4M. Regarding current trading prices, DXCM is priced at $62.22, while SIBN trades at $13.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas SIBN's P/E ratio is -29.82. In terms of profitability, DXCM's ROE is +0.32%, compared to SIBN's ROE of -0.11%. Regarding short-term risk, DXCM is less volatile compared to SIBN. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check SIBN's competition here
DXCM vs TCMD Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, TCMD has a market cap of 559.7M. Regarding current trading prices, DXCM is priced at $62.22, while TCMD trades at $24.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas TCMD's P/E ratio is 30.00. In terms of profitability, DXCM's ROE is +0.32%, compared to TCMD's ROE of +0.09%. Regarding short-term risk, DXCM is less volatile compared to TCMD. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check TCMD's competition here
DXCM vs ZIMV Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, DXCM is priced at $62.22, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, DXCM's ROE is +0.32%, compared to ZIMV's ROE of -0.05%. Regarding short-term risk, DXCM is more volatile compared to ZIMV. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check ZIMV's competition here
DXCM vs BWAY Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, BWAY has a market cap of 532.3M. Regarding current trading prices, DXCM is priced at $62.22, while BWAY trades at $13.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas BWAY's P/E ratio is 75.39. In terms of profitability, DXCM's ROE is +0.32%, compared to BWAY's ROE of +0.11%. Regarding short-term risk, DXCM is more volatile compared to BWAY. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check BWAY's competition here
DXCM vs NPCE Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, NPCE has a market cap of 493.2M. Regarding current trading prices, DXCM is priced at $62.22, while NPCE trades at $14.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas NPCE's P/E ratio is -22.20. In terms of profitability, DXCM's ROE is +0.32%, compared to NPCE's ROE of -1.06%. Regarding short-term risk, DXCM is less volatile compared to NPCE. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check NPCE's competition here
DXCM vs OFIX Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, OFIX has a market cap of 462.9M. Regarding current trading prices, DXCM is priced at $62.22, while OFIX trades at $11.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas OFIX's P/E ratio is -4.95. In terms of profitability, DXCM's ROE is +0.32%, compared to OFIX's ROE of -0.20%. Regarding short-term risk, DXCM is more volatile compared to OFIX. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check OFIX's competition here
DXCM vs VREX Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, VREX has a market cap of 440.2M. Regarding current trading prices, DXCM is priced at $62.22, while VREX trades at $10.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas VREX's P/E ratio is -6.40. In terms of profitability, DXCM's ROE is +0.32%, compared to VREX's ROE of -0.14%. Regarding short-term risk, DXCM is more volatile compared to VREX. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check VREX's competition here
DXCM vs KIDS Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, KIDS has a market cap of 406M. Regarding current trading prices, DXCM is priced at $62.22, while KIDS trades at $16.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas KIDS's P/E ratio is -9.50. In terms of profitability, DXCM's ROE is +0.32%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, DXCM is less volatile compared to KIDS. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check KIDS's competition here
DXCM vs PACB Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, PACB has a market cap of 404.7M. Regarding current trading prices, DXCM is priced at $62.22, while PACB trades at $1.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas PACB's P/E ratio is -0.74. In terms of profitability, DXCM's ROE is +0.32%, compared to PACB's ROE of -11.23%. Regarding short-term risk, DXCM is less volatile compared to PACB. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check PACB's competition here
DXCM vs VMD Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, VMD has a market cap of 371.7M. Regarding current trading prices, DXCM is priced at $62.22, while VMD trades at $9.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas VMD's P/E ratio is 26.03. In terms of profitability, DXCM's ROE is +0.32%, compared to VMD's ROE of +0.11%. Regarding short-term risk, DXCM is less volatile compared to VMD. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check VMD's competition here
DXCM vs CERS Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, CERS has a market cap of 357.4M. Regarding current trading prices, DXCM is priced at $62.22, while CERS trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas CERS's P/E ratio is -23.25. In terms of profitability, DXCM's ROE is +0.32%, compared to CERS's ROE of -0.26%. Regarding short-term risk, DXCM is less volatile compared to CERS. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check CERS's competition here
DXCM vs LAB Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, LAB has a market cap of 354.1M. Regarding current trading prices, DXCM is priced at $62.22, while LAB trades at $0.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas LAB's P/E ratio is -6.05. In terms of profitability, DXCM's ROE is +0.32%, compared to LAB's ROE of -0.18%. Regarding short-term risk, DXCM is less volatile compared to LAB. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check LAB's competition here
DXCM vs DCTH Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, DCTH has a market cap of 334.6M. Regarding current trading prices, DXCM is priced at $62.22, while DCTH trades at $9.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas DCTH's P/E ratio is 137.57. In terms of profitability, DXCM's ROE is +0.32%, compared to DCTH's ROE of +0.03%. Regarding short-term risk, DXCM is more volatile compared to DCTH. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check DCTH's competition here
DXCM vs CATX Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, CATX has a market cap of 324.9M. Regarding current trading prices, DXCM is priced at $62.22, while CATX trades at $4.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas CATX's P/E ratio is -3.13. In terms of profitability, DXCM's ROE is +0.32%, compared to CATX's ROE of -0.41%. Regarding short-term risk, DXCM is less volatile compared to CATX. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check CATX's competition here
DXCM vs SMLR Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, DXCM is priced at $62.22, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas SMLR's P/E ratio is 3.92. In terms of profitability, DXCM's ROE is +0.32%, compared to SMLR's ROE of +0.16%. Regarding short-term risk, DXCM is more volatile compared to SMLR. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check SMLR's competition here
DXCM vs SENS Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, SENS has a market cap of 288.2M. Regarding current trading prices, DXCM is priced at $62.22, while SENS trades at $6.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas SENS's P/E ratio is -4.16. In terms of profitability, DXCM's ROE is +0.32%, compared to SENS's ROE of -1.04%. Regarding short-term risk, DXCM is less volatile compared to SENS. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check SENS's competition here
DXCM vs CLPT Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, CLPT has a market cap of 278.7M. Regarding current trading prices, DXCM is priced at $62.22, while CLPT trades at $9.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas CLPT's P/E ratio is -10.41. In terms of profitability, DXCM's ROE is +0.32%, compared to CLPT's ROE of -1.22%. Regarding short-term risk, DXCM is less volatile compared to CLPT. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check CLPT's competition here
DXCM vs RXST Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, RXST has a market cap of 274M. Regarding current trading prices, DXCM is priced at $62.22, while RXST trades at $6.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas RXST's P/E ratio is -6.99. In terms of profitability, DXCM's ROE is +0.32%, compared to RXST's ROE of -0.14%. Regarding short-term risk, DXCM is less volatile compared to RXST. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check RXST's competition here
DXCM vs MASS Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, MASS has a market cap of 247.1M. Regarding current trading prices, DXCM is priced at $62.22, while MASS trades at $6.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas MASS's P/E ratio is -7.11. In terms of profitability, DXCM's ROE is +0.32%, compared to MASS's ROE of +0.13%. Regarding short-term risk, DXCM is less volatile compared to MASS. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check MASS's competition here
DXCM vs MGRM Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, DXCM is priced at $62.22, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas MGRM's P/E ratio is -11.11. In terms of profitability, DXCM's ROE is +0.32%, compared to MGRM's ROE of -1.11%. Regarding short-term risk, DXCM is more volatile compared to MGRM. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check MGRM's competition here
DXCM vs CVRX Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, CVRX has a market cap of 237.1M. Regarding current trading prices, DXCM is priced at $62.22, while CVRX trades at $9.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas CVRX's P/E ratio is -4.42. In terms of profitability, DXCM's ROE is +0.32%, compared to CVRX's ROE of -0.99%. Regarding short-term risk, DXCM is less volatile compared to CVRX. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check CVRX's competition here
DXCM vs NVRO Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, DXCM is priced at $62.22, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas NVRO's P/E ratio is -1.91. In terms of profitability, DXCM's ROE is +0.32%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, DXCM is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check NVRO's competition here
DXCM vs ANIK Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, ANIK has a market cap of 213.4M. Regarding current trading prices, DXCM is priced at $62.22, while ANIK trades at $14.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas ANIK's P/E ratio is -21.14. In terms of profitability, DXCM's ROE is +0.32%, compared to ANIK's ROE of -0.07%. Regarding short-term risk, DXCM is more volatile compared to ANIK. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check ANIK's competition here
DXCM vs EYES Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, EYES has a market cap of 210M. Regarding current trading prices, DXCM is priced at $62.22, while EYES trades at $4.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas EYES's P/E ratio is N/A. In terms of profitability, DXCM's ROE is +0.32%, compared to EYES's ROE of -3.17%. Regarding short-term risk, DXCM is less volatile compared to EYES. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check EYES's competition here
DXCM vs AVR Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, AVR has a market cap of 202.3M. Regarding current trading prices, DXCM is priced at $62.22, while AVR trades at $5.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas AVR's P/E ratio is -2.16. In terms of profitability, DXCM's ROE is +0.32%, compared to AVR's ROE of -5.28%. Regarding short-term risk, DXCM is less volatile compared to AVR. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check AVR's competition here
DXCM vs PROF Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, PROF has a market cap of 194.6M. Regarding current trading prices, DXCM is priced at $62.22, while PROF trades at $6.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas PROF's P/E ratio is -4.56. In terms of profitability, DXCM's ROE is +0.32%, compared to PROF's ROE of -0.80%. Regarding short-term risk, DXCM is less volatile compared to PROF. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check PROF's competition here
DXCM vs ELMD Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, ELMD has a market cap of 194.3M. Regarding current trading prices, DXCM is priced at $62.22, while ELMD trades at $23.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas ELMD's P/E ratio is 22.61. In terms of profitability, DXCM's ROE is +0.32%, compared to ELMD's ROE of +0.20%. Regarding short-term risk, DXCM is more volatile compared to ELMD. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check ELMD's competition here
DXCM vs BSGM Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, DXCM is priced at $62.22, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas BSGM's P/E ratio is -5.81. In terms of profitability, DXCM's ROE is +0.32%, compared to BSGM's ROE of +17.60%. Regarding short-term risk, DXCM is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check BSGM's competition here
DXCM vs SGHT Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, SGHT has a market cap of 190.1M. Regarding current trading prices, DXCM is priced at $62.22, while SGHT trades at $3.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas SGHT's P/E ratio is -4.76. In terms of profitability, DXCM's ROE is +0.32%, compared to SGHT's ROE of -0.56%. Regarding short-term risk, DXCM is less volatile compared to SGHT. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check SGHT's competition here
DXCM vs MDGS Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, DXCM is priced at $62.22, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas MDGS's P/E ratio is -0.27. In terms of profitability, DXCM's ROE is +0.32%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, DXCM is less volatile compared to MDGS. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check MDGS's competition here
DXCM vs QTRX Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, QTRX has a market cap of 177.9M. Regarding current trading prices, DXCM is priced at $62.22, while QTRX trades at $3.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas QTRX's P/E ratio is -1.51. In terms of profitability, DXCM's ROE is +0.32%, compared to QTRX's ROE of -0.35%. Regarding short-term risk, DXCM is less volatile compared to QTRX. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check QTRX's competition here
DXCM vs QTI Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, QTI has a market cap of 177.7M. Regarding current trading prices, DXCM is priced at $62.22, while QTI trades at $6.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas QTI's P/E ratio is -3.26. In terms of profitability, DXCM's ROE is +0.32%, compared to QTI's ROE of +3.64%. Regarding short-term risk, DXCM is less volatile compared to QTI. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check QTI's competition here
DXCM vs INGN Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, INGN has a market cap of 169.1M. Regarding current trading prices, DXCM is priced at $62.22, while INGN trades at $6.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas INGN's P/E ratio is -7.22. In terms of profitability, DXCM's ROE is +0.32%, compared to INGN's ROE of -0.12%. Regarding short-term risk, DXCM is less volatile compared to INGN. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check INGN's competition here
DXCM vs QIPT Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, DXCM is priced at $62.22, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas QIPT's P/E ratio is -15.87. In terms of profitability, DXCM's ROE is +0.32%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, DXCM is more volatile compared to QIPT. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check QIPT's competition here
DXCM vs TLSI Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, TLSI has a market cap of 160.7M. Regarding current trading prices, DXCM is priced at $62.22, while TLSI trades at $4.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas TLSI's P/E ratio is -2.30. In terms of profitability, DXCM's ROE is +0.32%, compared to TLSI's ROE of +1.37%. Regarding short-term risk, DXCM is less volatile compared to TLSI. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check TLSI's competition here
DXCM vs APYX Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, APYX has a market cap of 153.9M. Regarding current trading prices, DXCM is priced at $62.22, while APYX trades at $3.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas APYX's P/E ratio is -13.63. In terms of profitability, DXCM's ROE is +0.32%, compared to APYX's ROE of -1.18%. Regarding short-term risk, DXCM is less volatile compared to APYX. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check APYX's competition here
DXCM vs NNOX Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, NNOX has a market cap of 153.7M. Regarding current trading prices, DXCM is priced at $62.22, while NNOX trades at $2.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas NNOX's P/E ratio is -2.74. In terms of profitability, DXCM's ROE is +0.32%, compared to NNOX's ROE of -0.32%. Regarding short-term risk, DXCM is less volatile compared to NNOX. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check NNOX's competition here
DXCM vs SNWV Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, SNWV has a market cap of 145.2M. Regarding current trading prices, DXCM is priced at $62.22, while SNWV trades at $16.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas SNWV's P/E ratio is 41.22. In terms of profitability, DXCM's ROE is +0.32%, compared to SNWV's ROE of -1.42%. Regarding short-term risk, DXCM is less volatile compared to SNWV. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check SNWV's competition here
DXCM vs EDAP Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, EDAP has a market cap of 127.1M. Regarding current trading prices, DXCM is priced at $62.22, while EDAP trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas EDAP's P/E ratio is -4.35. In terms of profitability, DXCM's ROE is +0.32%, compared to EDAP's ROE of -1.15%. Regarding short-term risk, DXCM is less volatile compared to EDAP. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check EDAP's competition here
DXCM vs LUCD Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, LUCD has a market cap of 116.6M. Regarding current trading prices, DXCM is priced at $62.22, while LUCD trades at $1.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas LUCD's P/E ratio is -1.65. In terms of profitability, DXCM's ROE is +0.32%, compared to LUCD's ROE of -5.91%. Regarding short-term risk, DXCM is more volatile compared to LUCD. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check LUCD's competition here
DXCM vs FONR Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, FONR has a market cap of 114.8M. Regarding current trading prices, DXCM is priced at $62.22, while FONR trades at $18.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas FONR's P/E ratio is 16.17. In terms of profitability, DXCM's ROE is +0.32%, compared to FONR's ROE of +0.04%. Regarding short-term risk, DXCM is more volatile compared to FONR. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check FONR's competition here
DXCM vs ICAD Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, DXCM is priced at $62.22, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas ICAD's P/E ratio is -20.37. In terms of profitability, DXCM's ROE is +0.32%, compared to ICAD's ROE of -0.06%. Regarding short-term risk, DXCM is more volatile compared to ICAD. This indicates potentially higher risk in terms of short-term price fluctuations for DXCM.Check ICAD's competition here
DXCM vs RPID Comparison April 2026
DXCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DXCM stands at 24.3B. In comparison, RPID has a market cap of 103.2M. Regarding current trading prices, DXCM is priced at $62.22, while RPID trades at $2.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DXCM currently has a P/E ratio of 29.77, whereas RPID's P/E ratio is -2.27. In terms of profitability, DXCM's ROE is +0.32%, compared to RPID's ROE of -0.95%. Regarding short-term risk, DXCM is less volatile compared to RPID. This indicates potentially lower risk in terms of short-term price fluctuations for DXCM.Check RPID's competition here